Even as the tech industry continues to grapple with the prolonged funding winter, biotech startups in Southeast Asia have proved to be an outlier this year. 2023 has also seen a few big funds being launched focusing on the biotech and life science sectors, signalling strong investor appetite in the industry.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
